TABLE 1.
Antibiotic resistance profiles of CRKP isolates
| Group or regimen | % of isolates resistant to:a |
|||||||
|---|---|---|---|---|---|---|---|---|
| AMK (137) | GEN (140) | LVX (140) | MIN (5) | PMB (100) | TGC (130) | TOB (120) | SXT (114) | |
| All treatment groups | 68 | 36 | 92 | 0 | 14 | 5 | 93 | 84 |
| SAA without a BL (n = 32) | 71 | 35 | 89 | 0 | 9 | 3 | 91 | 75 |
| SAA plus a BL (n = 36) | 66 | 44 | 90 | N/A | 18 | 3 | 93 | 92 |
| MAA without a BL (n = 40) | 67 | 33 | 88 | 0 | 11 | 5 | 91 | 82 |
| MAA plus a BL (n = 33) | 73 | 33 | 100 | 0 | 18 | 6 | 94 | 89 |
a
AMK, amikacin; GEN, gentamicin; LVX, levofloxacin; MIN, minocycline; PMB, polymyxin B; TGC, tigecycline; TOB, tobramycin; SXT, trimethoprim-sulfamethoxazole; SAA, single active agent; BL, beta-lactam antibiotic; MAA, multiple active agents. The number of isolates for which MICs were reported is indicated in parentheses next to the abbreviation.